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a b s t r a c t
Passive transmission of autoimmune diseases by allogeneic stem cell transplantation is rare
and is ascribed to passive transfer of memory B-cells from donor to recipient. We hereby
report a case of transmission of an asymptomatic lupus anticoagulant from a sibling donor
to a recipient of transplantation for secondary acute myeloid leukemia. On pre-harvest eval-
uation, the sibling donorwith nohistory of bleeding or thrombosiswas found to have a lupus
anticoagulant. After engraftment, the recipientwas found to have anewprolonged activated
partial thromboplastin time and was subsequently shown to have a lupus anticoagulant on
Day +73 after stem cell transplantation. The recipient remained well with no evidence of
bleeding, thrombosis, or graft-versus-host disease and was on a stable dose of tacrolimus at
the time the lupus anticoagulant was detected. There was no other identiﬁable trigger for
the appearance of a lupus anticoagulant.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
been any previously reported cases of the asymptomaticntroduction
llogeneic stem cell transplantation (SCT) is a potentially
urative procedure for patients with hematological malig-
ancies. Bone marrow and peripheral blood stem cells from
elated and unrelated donors are subject to a comprehen-
ive evaluation to prevent the transmission of communicable
iseases.1,2 Few cases illustrating the transmission of autoim-
une disease by SCT have been reported in the literature.
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eserved.Such phenomena were attributed to the transmission of
donor lymphocytes with SCT. The lupus anticoagulants
(LAC) are heterogeneous antibodies that bind to a com-
plex of anionic phospholipids that bind to one or more
blood coagulation proteins to inﬂuence their contribution in
coagulant-based assays.3 To our knowledge, there had notiversity Hospitals Case Medical Center, 11100 Euclid Avenue, LKS
transmission of LAC by SCT. We hereby report a case of
transmission of a LAC from a sibling donor to a recipient
by SCT.
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Case report
A63-year-oldCaucasianmale,withno signiﬁcantpastmedical
history, was initially diagnosed with myelodysplastic syn-
drome with French, American and British (FAB) classiﬁcation
of refractory anemia with excess blasts; with complex cyto-
genetics and a revised international prognostic scoring system
(IPSS-R) of 8.5.4 A bone marrow biopsy showed 6% blasts
at the time of diagnosis. The patient received two cycles
of azacitidine (75mg/m2 for seven doses). A repeat bone
marrow biopsy showed transformation to secondary acute
myeloid leukemia (AML) FAB subtype M6. The patient received
induction chemotherapywith cytarabine (100mg/m2 for seven
doses) and idarubicin (12mg/m2 for three doses) and achieved
minimal residual disease with a markedly hypocellular mar-
row and no residual blasts. Given the high risk nature of his
disease, the patient proceeded to allogeneic peripheral blood
stem cell transplantation from his human leukocyte antigen-
(HLA) and ABO-identical brother. The transplant conditioning
regimen included ﬂudarabine (daily dose of 30mg/m2 on Days
−5 to −2) and melphalan (140mg/m2 on Day −2). Immunosup-
pression consisted of tacrolimus and methotrexate (10mg/m2
on Days +1, +3, +6, +11). Post-transplant course was com-
plicated with Klebsiella pneumonia and vancomycin resistant
enterococci bacteremia. The patient engrafted white cells on
Day +15. On Day +73 the patient was doing well without
evidence of graft-versus-host disease (GVHD), thrombosis, or
bleeding. He had an isolated prolongation of activated par-
tial thromboplastin time (aPTT) of 56 s (normal range: 23–35).
The patient’s baseline value for aPTT prior to transplantation
was 31 s. The prothrombin time (PT) was 12.9 s (normal range:
9.3–12.8). The thrombin time was normal excluding heparin
contamination. Mixing studies failed to correct the prolonged
aPTT. Dilute Russell Viper venom time (DRVVT) was 109.7 s
(normal range: <55.1 s). DRVVT conﬁrmatory test was 47.2 s
with a ratio of 2.2 (normal range: <1.3) demonstrating strong
serologic evidence of a lupus anticoagulant (LAC). Serologic
testing for anticardiolipin antibodies (IgG, IgM, IgA) and 2
glycoprotein I antibodies (IgG, IgM, IgA) was negative. The ele-
vated PTT persisted. The patient’s sibling donor was found to
have a prolonged aPTT of 56 s prior to donation. The screening
test for DRVVT was 125.9; the conﬁrmatory test was 41.7 with
a ratio of 2.8 also indicating strong serologic evidence of LAC.
These ﬁndings suggest the transmission of LAC from sibling
donor to recipient.
Discussion
Autoimmune syndromes and autoantibodies are suspected
to develop after autologous and allogeneic SCT. In a retro-
spective analysis of 1292 patients of post-transplantation (465
autologous and 827 allogeneic), 3% of patients developed a
de novo LAC.5 The development of LAC in this analysis was
related to the use of cyclosporine A, use of T-cell depletion for
GVHD prophylaxis, use of a busulfan and cyclophosphamide
(BUCY) regimen, and reactivation of cytomegalovirus (CMV)
or other herpes viruses.5 Autoantibody production after SCT
has been ascribed to de novo antibody production from naive2014;36(4):287–289
B-cells or passive transfer ofmemory B-cells from the donor.6,7
B-cell functional recovery after SCT is slow and incomplete
often resulting in seronegativity to previous immunizations;
regardless of the immune status of the donor.8 Tracking of
transferred B-cell clones showed that production of antigen-
speciﬁc plasma cells from donor memory B-cell pool requires
further exposure to antigen yet results in the production of
antibodies with identical afﬁnity to those produced in the
donor.9
Antiphospholipid antibodies (aPL) are autoantibodies
directed against phospholipid binding proteins that most
commonly are 2-glycoprotein I, cardiolipin, and many blood
coagulation proteins. LACs are aPL that interact with blood
coagulation proteins and inﬂuence clot-based blood coagula-
tion protein assays. The presence of lupus anticoagulants in
healthy individuals has been estimated to be 1.0–5.6% while
in individuals with systemic lupus erythematosus (SLE) it is
much higher; 11–86%.10 The presence of LACs, in the absence
of any history of bleeding or thrombosis, is frequently dis-
covered by routine aPTT screening performed prior to an
elective surgical procedure. The diagnosis of antiphospho-
lipid syndrome (APLS) requires evidence of arterial or venous
thrombosis or pregnancy morbidity associated with the detec-
tion of aPL antibodies on two separate occasions at least 12
weeks apart.3,10 Inhealthy individualswithout SLE, the clinical
signiﬁcance of persistent asymptomatic aPL remains uncer-
tain and the risk of development of thrombosis is unknown.10
APLS occurrence after SCT has been reported before but only
in the context of acute/chronic GVHD and associated with
cerebral thrombosis and catastrophic APLS.11–15
Ritchie et al. 13 described a case of the transmission of APLS
from a sibling donor with known SLE, APLS, and history of
thrombosis where the recipient developed symptomatic APLS
with cerebral thrombosis and also a high titer anticardiolipin
and anti-ds-DNAantibodies (identical to donor). In that report,
aPL positivity was predated by the onset of chronic GVHD six
months after SCT suggesting that memory B-cell activation
occurred as the result of thepresentationof phospholipid anti-
gens from epithelial tissue induced by GVHD. In our case, we
had prior knowledge that the sibling donor had LAC, yet we
decided to proceed with SCT as we believed that the bene-
ﬁt in proceeding to SCT quickly, as the patient had a high
risk for AML relapse, outweighed the theoretical risk of the
development of symptomatic APLS. We cannot exclude the
possibility of the development of a de novo autoimmune LAC
in the recipient, independent of the transmission of donor
lymphocytes capable of producing aPL (including LAC). Cell
membrane damage, related to the toxicity from the condi-
tioning regimen, may expose antigens, such as the hexagonal
phase lipids, that are not otherwise present in the intact cell
membrane. Such lipid could serve as an epitope for the devel-
opment of LAC or other aPL as a de novo phenomenon.16 We
believe that this possibility is less likely in the current case
as the patient received a reduced-intensity conditioning reg-
imen, had no evidence of GVHD, and was on a stable dose of
tacrolimus at the time of the detection of the LAC. Our obser-
vations suggest the passive transfer of donor B-cells capable
of producing a LAC. The antigen trigger for development of the
LAC in our case remains obscure and may be related to infec-
tious complications occurring in the peri-transplant period.
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